Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
Eleni Panagioti(Beth Israel Deaconess Medical Center), Evanthia Galanis(Mayo Clinic in Arizona)
Cited by 61
Related Papers
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
|Neuro-Oncology|2015|665